Intravenous immunoglobulin for the treatment of severe maternal alloimmunization: individual patient data meta-analysis - 09/05/24
, Enaja V. Sambatur, MD c, Giorgio Pagani, MD d, Francesco D’Antonio, MD e, Emeline Maisonneuve, MD f, g, Paul Maurice, MD g, Carolien Zwiers, MD h, Joanne E.J.T. Verweij, MD h, Anna Flood, BS a, Alireza A. Shamshirsaz, MD c, Jean-Marie Jouannic, MD g, Asma Khalil, MD i, jAbstract |
Objective |
This study aimed to investigate the outcomes associated with the administration of maternal intravenous immunoglobulin in high-risk red blood cell–alloimmunized pregnancies.
Data Sources |
Medline, Embase, and Cochrane Library were systematically searched until June 2023.
Study Eligibility Criteria |
This review included studies reporting on pregnancies with severe red blood cell alloimmunization, defined as either a previous fetal or neonatal death or the need for intrauterine transfusion before 24 weeks of gestation in the previous pregnancy as a result of hemolytic disease of the fetus and newborn.
Methods |
Cases were pregnancies that received intravenous immunoglobulin, whereas controls did not. Individual patient data meta-analysis was performed using the Bayesian framework.
Results |
Individual patient data analysis included 8 studies consisting of 97 cases and 97 controls. Intravenous immunoglobulin was associated with prolonged delta gestational age at the first intrauterine transfusion (gestational age of current pregnancy − gestational age at previous pregnancy) (mean difference, 3.19 weeks; 95% credible interval, 1.28–5.05), prolonged gestational age at the first intrauterine transfusion (mean difference, 1.32 weeks; 95% credible interval, 0.08–2.50), reduced risk of fetal hydrops at the time of first intrauterine transfusion (incidence rate ratio, 0.19; 95% credible interval, 0.07–0.45), reduced risk of fetal demise (incidence rate ratio, 0.23; 95% credible interval, 0.10–0.47), higher chances of live birth at ≥28 weeks (incidence rate ratio, 1.88; 95% credible interval, 1.31–2.69;), higher chances of live birth at ≥32 weeks (incidence rate ratio, 1.93; 95% credible interval, 1.32–2.83), and higher chances of survival at birth (incidence rate ratio, 1.82; 95% credible interval, 1.30–2.61). There was no substantial difference in the number of intrauterine transfusions, hemoglobin level at birth, bilirubin level at birth, or survival at hospital discharge for live births.
Conclusion |
Intravenous immunoglobulin treatment in pregnancies at risk of severe early hemolytic disease of the fetus and newborn seems to have a clinically relevant beneficial effect on the course and severity of the disease.
Le texte complet de cet article est disponible en PDF.Video |
(10.42 Mo)
Key words : blood transfusion, erythroblastosis, fetal, immunoglobulin, intrauterine, intravenous, meta-analysis, systematic review
Plan
| The authors report no conflict of interest. |
|
| No external funding has been received for this study. |
|
| This study was registered on the International Prospective Register of Systematic Reviews (registration number: CRD42023428301) on May 31, 2023. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?